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days with ≥ 50% decreased household productivity (mean BL:10.5, C/W:1.2), RA inter-
ference with household productivity (mean BL:6.2, C/W:2.0) and days missed per 
month of family/social/leisure activity (mean BL:5.8, C/W:0.7). ConClusions: In 
the RAPID1 OLE, CZP Q2W plus MTX maintained improvements in workplace and 
household productivity and increased social activity participation over > 4yrs.
PMS87
Continued iMProveMentS in WorkPlaCe and HouSeHold ProduCtivity 
WitH CertolizuMab Pegol treatMent in axial SPondyloartHritiS, 
inCluding ankyloSing SPondylitiS and non-radiograPHiC axial 
SPondyloartHritiS: 48-Week reSultS froM tHe raPid-axSPa Study
van der Heijde D.1, Braun J.2, Rudwaleit M.3, Purcaru O.4, Kavanaugh A.5
1Leiden University Medical Centre, Leiden, The Netherlands, 2Rheumazentrum Ruhrgebiet, Herne, 
Germany, 3Endokrinologikum Berlin, Berlin, Germany, 4UCB Pharma, Brussels, Belgium, 5UCSD, 
San Diego, CA, USA
objeCtives: Investigate certolizumab pegol (CZP) effect on workplace and house-
hold productivity up to 48 weeks (wks) in patients (pts) with axial spondyloarthritis 
(axSpA), including ankylosing spondylitis (AS, meeting modified New York criteria) 
and non-radiographic axSpA (nr-axSpA). Methods: The ongoing RAPID-axSpA 
trial (NCT01087762) is double-blind and placebo-controlled to Wk24 and dose-
blind to Wk48. Pts had active axSpA, according to ASAS criteria, including AS and 
nr-axSpA. Pts originally randomized to CZP (200mg Q2W or 400mg Q4W, following 
400mg loading dose at Wks 0, 2, 4) continued on their assigned dose in dose-blind 
phase; placebo pts entering dose-blind phase were re-randomized to CZP loading 
dose, followed by CZP 200mg Q2W or 400mg Q4W. The validated arthritis-specific 
Work Productivity Survey (WPS; administered Q4W) assessed the impact of axSpA 
on workplace and household productivity. WPS responses (LOCF imputation) in 
pts originally randomized to CZP in the full analysis set (FAS) are summarized 
descriptively over 48 wks. Results: A total of 325 pts were randomized, of which 
218 were assigned to CZP 200mg Q2W or CZP 400mg Q4W. 69.4% and 74.9% of pts 
were employed at baseline (BL) in the CZP 200mg Q2W and CZP 400mg Q4W groups, 
respectively. By Wk48, employed CZP pts reported reduced workplace absenteeism 
(Wk48: mean 0.4 and 0.1 days missed/month for CZP 200 mg Q2W and 400 mg 
Q4W, respectively vs BL: mean 2.3 and 1.4 days/month) and presenteeism (Wk48: 
mean 1.0 and 1.6 days with reduced productivity/month vs BL: mean 5.8 and 4.7 
days/month). Continued improvements in both CZP groups to Wk48 were also 
observed in household productivity and participation in social/leisure activities. 
Similar improvements were seen in AS and nr-axSpA populations. ConClusions: 
The initial improvements with CZP in workplace and household productivity and 
increased participation in social/leisure activities observed over 24 wks were con-
tinued to Wk48 in axSpA, AS and nr-axSpA pts.
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objeCtives: To examine the effect of certolizumab pegol (CZP) on workplace and 
household productivity up to 48 weeks (wks), in patients (pts) with active psoriatic 
arthritis (PsA). Methods: The ongoing RAPID-PsA trial (NCT01087788) is double-blind 
and placebo-controlled to Wk24 and dose-blind to Wk48. Pts had active PsA and had 
failed ≥ 1 DMARD. Pts originally randomized to CZP (200mg Q2W or 400mg Q4W, follow-
ing 400mg loading dose at Wks 0, 2, 4) continued on their assigned dose in dose-blind 
phase; placebo pts entering dose-blind phase were re-randomized to CZP loading dose, 
followed by CZP 200mg Q2W or CZP 400mg Q4W. This publication reports data for pts in 
the randomised set (RS) originally randomized to CZP. The validated arthritis-specific 
Work Productivity Survey (WPS), administered Q4W from baseline (BL), assessed the 
impact of PsA on workplace and household productivity. WPS responses (LOCF impu-
tation) in both CZP groups are summarized descriptively over 48 wks. Results: 409 
pts were randomized, of which 273 were assigned to CZP 200mg Q2W or CZP 400mg 
Q4W. 87% of patients randomized to CZP completed to Wk48. 60.1% and 61.5% were 
employed at BL in the CZP 200mg Q2W and CZP 400mg Q4W groups, respectively. 
By Wk48, employed CZP pts reported reduced workplace absenteeism (Wk48: mean 
0.1 and 0.6 days missed/month for CZP 200mg Q2W and 400mg Q4W, respectively vs 
BL: mean 2.0 and 1.6 days/month) and presenteeism (Wk48: mean 0.8 and 1.9 days 
with reduced productivity/month vs BL: mean 5.2 and 5.1 days/month). CZP groups 
also reported improvements in household productivity and increased participation 
in social/leisure activities up to Wk48. ConClusions: The initial improvements with 
CZP in workplace and household productivity, and participation in social/leisure activi-
ties observed over 24 wks were maintained over 48 wks in PsA pts.
PMS89
faCtorS aSSoCiated WitH abSenteeiSM in rHeuMatoid artHritiS 
PatientS in eMPloyMent: reSultS of a Survey aMong frenCH PatientS
Fagnani F.1, Duburcq A.1, Woronoff A.S.2, Chauvin P.3, Cukierman G.4, Tropé-Chirol S.2, 
Joubert J.M.4, Bertin P.5
1Cemka-Eval, Bourg la Reine, France, 2ANDAR, Paris, France, 3INSERM, Paris, France, 4UCB 
Pharma, Colombes, France, 5CHU Dupuytren, Limoges, France
objeCtives: To investigate the contribution of different socio-economic and clinical 
factors to absenteeism in the workplace in a population of Rheumatoid Arthritis (RA) 
patients currently in employment. Methods: A national retrospective survey was 
conducted in French RA patients (age < 60, either employed or unemployed) recruited 
by rheumatologists or who were members of a patients’ association (ANDAR). Patient-
reported outcomes, socio-economic characteristics and various measures of pro-
ductivity loss were collected using structured telephone interviews. Multivariate 
Wellness Survey, an Internet health survey administered to a representative sample 
of adults, were used. Respondents who reported experiencing OA, with the knee 
being the only joint affected, and who reported having had joint surgery in the past 
year were considered to have had a knee replacement. A matched control group was 
identified as a comparator to the knee replacement group by using a propensity 
score matching method (matching variables include demographics and health his-
tory). Knee replacement respondents and matched controls were compared with 
respect to the Short Form-36v2, activity impairment (from the Work Productivity 
and Activity Impairment questionnaire), and health care resource utilization using 
ANOVA tests. Results: A total of 102 respondents were identified as part of the 
knee replacement group (52.0% male, 57.9 years). Compared with matched con-
trols (n= 102), those in the knee replacement group reported significantly worse 
physical health status (42.5 vs. 47.6, p< .05) though equivalent mental health status 
(49.7 vs. 49.0, p= .67). Levels of activity impairment (38.0% vs. 27.0% impairment, 
p< .05) and health care resource utilization (physician visits: 7.3 vs. 4.5, p< .05; emer-
gency room visits: 0.6 vs. 0.2, p< .05; and hospitalizations: 0.6 vs. 0.2, p< .05) were 
all significantly higher among the knee replacement group relative to matched 
controls. ConClusions: These results suggest a significant burden among knee 
replacement respondents across both health status and economic outcomes. 
Improved management of these patients may have significant societal benefits.
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objeCtives: Inflammatory diseases such as rheumatoid arthritis (RA), psoriatic 
arthritis (PsA) and axial spondyloarthritis (axSpA) are associated with significant 
burden on patients’ (pts) health-related quality of life (HRQoL). The objective was to 
compare HRQoL across RA, PsA and axSpA populations. Methods: Baseline data 
used from: RA pooled RAPID1 (NCT00152386) and RAPID2 (NCT00160602), RAPID-
PsA (NCT01087788) and RAPID-axSpA (NCT01087762). Differences between SF-36 
HRQoL scores and US general population age/gender-matched population norms 
were calculated and descriptively compared between the overall RA, PsA and axSpA 
populations, PsA subpopulations with skin involvement (≥ 3% body surface area) and 
without, and axSpA subpopulations of ankylosing spondylitis (AS) and non-radio-
graphic axSpA (nr-axSpA). Physical function was assessed using HAQ-DI in RA and 
PsA, and was also compared between PsA subpopulations. Results: Comparison of 
SF-36 score decrement vs population norms (mean±SD) revealed axSpA pts (N= 317) 
experienced a higher burden on overall physical HRQoL (-19.3±7.5) compared to RA 
(N= 1535; -17.4±7.0) and PsA (N= 403; -16.6±8.0) pts, while RA pts reported a higher 
psychological burden (-11.3±11.2) compared to axSpA (-9.3±12.3) and PsA (-8.6±12.2) 
pts. Comparison of HAQ-DI scores revealed RA pts experienced greater difficulties in 
all physical function aspects assessed, compared to PsA pts. For axSpA pts, the burden 
of disease (SF-36 scores) was similar between AS and nr-axSpA subgroups. For PsA pts, 
comparison of HRQoL scores confirmed that skin involvement does not significantly 
add to the physical health burden of disease but adds to some of the psycho-social 
aspects (eg. social function). ConClusions: Trends suggested axSpA had the high-
est burden on overall physical HRQoL followed by RA and PsA, while the burden on 
overall mental HRQoL was highest in RA followed by axSpA and PsA. HRQoL burden 
in axSpA did not appear different between subpopulations, however the presence 
of skin involvement in PsA was associated with a higher burden on social function.
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objeCtives: In the RAPID1 randomized controlled trial (RCT; NCT00152386), certoli-
zumab pegol (CZP) every 2 weeks (Q2W) plus MTX provided rapid improvements in 
clinical measures, and workplace and household productivity over 52 weeks (wks) 
in patients (pts) with active rheumatoid arthritis (RA). We report the long-term effect 
of CZP+MTX Q2W on workplace and household productivity and social participation 
in RA pts from the RAPID1 open-label extension (OLE; NCT00175877). Methods: 
RAPID1 52-wk Completers and Wk16 Withdrawers were eligible for treatment in OLE 
with CZP 400mg Q2W +MTX, reduced per study protocol to 200mg Q2W +MTX after 
≥ 6 months in OLE. Workplace and household productivity were assessed through 
the validated RA-specific Work Productivity Survey (WPS-RA). WPS-RA responses 
(observed cases) are summarized for CZP RCT Completers who enrolled in OLE and 
completed WPS-RA at OLE completion/withdrawal visit (C/W). Results: Of CZP 
Completers who enrolled in OLE (N= 508), 388 remained at Wk208 (4yrs) and a subset 
of 290 completed WPS-RA at OLE C/W (after minimum 4.3 and maximum 6.2 years 
CZP treatment from RCT baseline [BL]). Of these pts at RCT BL (N= 267), 49% were 
employed outside the home, 21% were RA work-disabled, 14% were homemakers 
and 13% were retired. Employed pts reported long-term reductions in absenteeism 
[mean BL:3.7 (N= 131), C/W:0.1 (N= 129)], number of days with decreased productiv-
ity (presenteeism) (mean BL:7.8, C/W:0.4) and level of RA interference with work 
productivity (mean BL:5.0, C/W:1.3, on 0–10 scale) per month. Similar decreases 
were reported in the number of household work days missed (mean BL:8.1, C/W:1.0), 
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private practices to collect de-identified data on patient diagnosis, treatment pat-
terns/dynamics and patient symptomatology/disease status. Physicians from the 
US were screened for duration of practice and patient volume and recruited from a 
large panel to be geographically representative. Eligible patient charts (> 6 biologic 
patients, > 2 biologic-suitable (and yet biologic-naïve) patients per physician judg-
ment) were randomly selected from a sample of prospective patients visiting each 
center/practice during the screening period. Results: Ninety-seven physicians 
abstracted 726 eligible RA patient charts; 378(52%) patients were on their first bio-
logic and 175(24%) patients have never experienced biologic but were considered 
suitable for one. Mean age was: 1st line-52.8yrs, biologic-suitable-51.5yrs; Female: 
1st line-73%, biologic-suitable-76%. Disease severity at diagnosis and current dis-
ease severity (both per physician judgment) (mild:moderate:severe) were: 1st line 
– 6%:74%:14% and 67%:29%:3%, biologic-suitable – 11%,74%, 10% and 25%:66%:9% 
respectively. Current drug class usage differed between the two groups (1st line/
biologic-suitable): non-biological-DMARD (57%/88%), steroids (19%/36%), NSAIDs-
COX2-inhibitors (6%/10%), NSAIDs- non-COX2-inhibitors (14%/22%), and analge-
sics (11%/12%). Key lab measures were (1st line/biologic-suitable): ESR(24.2/40.0 
mm/h) and CRP(2.5mg/5.6 dl). Current ACR-scores were (1st line/biologic-suita-
ble): no response(2%/19%), ACR20(12%/36%), ACR50(18%/15%), ACR70(20%/5%), 
ACR90(26%/1%). Among patients with available data, current HAQ (1st line-0.7, 
biological-suitable-1.1), DAS28 (1st line-2.5, biological-suitable-4.1), 100mmVAS 
(1st line-2.3, biological-suitable-4.6), Swollen Joint Count (1st line-2.0, biological-
suitable-5.9) and Tender Joint Count (1st line-2.8, biological-suitable-7.0) differed 
between the patient groups. ConClusions: Compared to the patients currently 
treated with 1st line biologic, RA biologic-naïve but suitable patients (per physician 
judgment) had relatively higher disease burden. Reasons for non-initiation of bio-
logic treatment among ‘biologic-suitable’ patients warrant further investigation to 
alleviate disease burden.
PMS93
CoMPariSon of diSeaSe StatuS, treatMentS and outCoMeS of 
PatientS WitH PSoriatiC artHritiS reCeiving tHeir firSt biologiC in 
tHe euroPean union and united StateS
Narayanan S.1, Baskett A.2, Lu Y.2, Hutchings R.2
1Ipsos Healthcare, Gaithersburg, MD, USA, 2Ipsos Healthcare, London, UK
objeCtives: To compare the disease status and outcomes of patients with PsA 
receiving their first biologic in UK, Germany, France, Italy and Spain (5EU) with 
the US. Methods: A multi-country multi-center medical chart-review study of 
PsA patients was conducted among physicians (majority: rheumatologists) in 
hospitals/private practices to collect de-identified data on patients who were 
recently treated with a biologic as part of usual care. Physicians were screened 
for duration of practice and patient volume and recruited from a large panel to 
be geographically representative in each country. Eligible PsA patient charts 
(> 3) were randomly selected from a sample of prospective patients visiting each 
center/practice during the screening period. Physicians abstracted patient diag-
nosis, treatment patterns/dynamics and patient symptomatology/disease status/
outcomes. Results: In 4Q2012, 434 physicians (5EU:337, US:97) abstracted 790 
eligible PsA patient charts (5EU:606, US:184); 674 (85%) (5EU:527, US:147) patients 
were on their first biologic (mean-age: 5EU:47.4yrs, US:47.6yrs; female: 5EU:48.6%, 
US:44.9%). Time-to-1st biologic from diagnosis (5EU:41.0months, US:27.2months) 
and time-on-current biologic (5EU:23.2months, US:36.7months) differed between 
regions. Top-2 biologic treatments observed were adalimumab (5EU:47%, US:47%) 
and etanercept (5EU:36%, US:32%). Among the top-4 reasons for biologic treatment 
initiation, ‘mechanism of action’, ‘improve signs/symptoms’, ‘positive personal 
experience’ and ‘prevention of structural damage’ were observed in both the 5EU 
and US. Key lab measures documented were: ESR (5EU:20.6mm/h, US:23.7mm/h) and 
CRP (5EU:9.4mg/dl, US:2.8mg/dl). Current disease severity per physician-judgment 
(mild:moderate:severe) was: 5EU-61%:33%:5%, US-73%:26%:1%. Among patients with 
available data, current HAQ (5EU:1.3, US:0.6), VAS provider score (5EU:3.1, US:2.6), 
VAS patient score (5EU:3.4, US:2.7) and Swollen Joint Count (5EU:2.0, US:1.7) differed 
across regions. ConClusions: Among PsA patients receiving their first biologic, 
disease severity and outcomes differed between 5EU and US, with patients in 5EU 
with relatively higher burden and poorer outcomes.
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objeCtives: To assess the patterns of disease remission among RA patients receiv-
ing their first biologic in 5-EU countries, namely, UK, Germany(DE), France(FR), 
Italy(IT) & Spain(SP). Methods: A multi-country multi-center medical chart-review 
study of RA patients was conducted among physicians (majority: rheumatologists) 
in hospitals/private practices to collect de-identified data on patients who were 
recently treated with a biologic as part of usual care. Physicians were screened 
for practice-duration and patient-volume and recruited from a large panel to be 
geographically representative in each country. Patient charts (> = 5) were randomly 
selected within each center/practice. Physicians abstracted patient diagnosis, 
treatment patterns/dynamics and patient symptomatology/disease status (incl. 
assessment of ‘disease remission’, per physician clinical judgment). Results: In 
4Q2011, 370 physicians abstracted 2208 eligible RA patient charts (UK:410, FR:499, 
DE:404, IT:415, SP:480); patient mean-age:51yrs, female:71%; 75% and 20% were on 
1st line and 2nd line biologic respectively. Overall, 53% of patients were in remis-
sion (UK:54%, FR:56%, DE:61%, IT:41%, SP:53%). Remission-rates differed by biologic 
lines: 1st-line:53%, 2nd-line:53%, 3rd-line:46%, 4th-line:42%, 5th-line:38%. Among those 
with lab measures, results differed between those in remission vs. those who were 
not: mean ESR(mm/h): 17.0vs.32.1, mean CRP(mg/dl): 7.0vs.15.6, mean MMP3(ng/
ml): 2.8-vs-4.7, Rheumatoid Factor (% positive): 83%-vs-86% and Anti-CCP (% posi-
tive): 75%-vs-79%. Among those with data, recent (mean) disease severity scores 
regression analyses were performed to identify the contributing factors to absentee-
ism. Results: A sample of 503 patients agreed to participate, of which 488 were 
evaluable. 364 patients (74.6%) were in employment, 31 (6.4%) were unemployed and 
93 (19.1%) were out of the labor market. Among the 364 patients currently in employ-
ment, 102 (28.0%), 138 (37.9%) and 124 (34.1%) were in ACR functional class of I, II and 
III/IV, respectively. The mean HAQ scores were 0.6, 1.4 and 1.5 (p< 0.0001), and 2.9%, 
16.7% and 29.0% (p< 0.0001), respectively, had an occupational disability status. An 
overall proportion of 48.3% patients declared an RA associated work absence over the 
last year. This proportion increased from 28.4% in ACR I to 62% in ACR III/IV group, 
and from 7.8% to 31.4% (p< 0.0001), respectively, for absence > 1 month. Despite a high 
uptake of biologic agents (60.4%) among these patients, RA was active for a significant 
period of time; mean 2.2 (±3.2) months in ACR I group and 4.8 (±4.2) months in ACR 
III/IV group. Regression analyses suggested that ACR functional class and frequencies 
and duration of flares were the major factors contributing to absenteeism, far ahead 
of any other socio-economic characteristics. ConClusions: Loss of productivity due 
to RA could be further reduced through better control of disease activity.
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objeCtives: Rheumatoid arthritis is an autoimmune chronic disease which is 
associated with an increasing disability of patients and high socioeconomic bur-
den. Given the large number of economic evaluations considered by national HTAs, 
this review attempts to clarify whether biologic DMARDs cost-effectiveness and 
cost-utility results form the basis for official recommendation by national HTA 
agencies. Methods: Both older biologic anti-TNFα drugs (etanercept, infliximab 
and adalimumab) and novel bDMARDs (abatacept, tocilizumab, certolizumab, goli-
mumab and rituximab) were considered. All main HTA agencies were searched 
for published economic evaluations up to 2012. Documents were selected if they 
included cost-effectiveness or cost-utility as outcome, if they referred to at least 
one of the drugs of interest, if they were published in English and if they were not 
superseded by other analysis. PICO statements were used to define exclusion crite-
ria. Results: Of the 65 documents initially identified through the search strategy, 
20 documents were selected. The associated HTA agencies were PBAC (Australia), 
CADTH (Canada), SMC (Scotland) and NICE (England). In relation to older anti-TNFα , 
documents published by NICE were found to be the only explicitly recommending 
the drugs on the basis of obtained cost-utility results. Economic evaluations of 
novel bDMARDs published by SMC and NICE appeared to inform HTA decisions not 
to recommend abatacept and to list all other drugs conditional on price facilitation 
and following failure of rituximab. By contrast, cost-utility analysis published by 
PBAC and CADTH did not appear to influence official recommendations on novel 
biologic DMARDs. ConClusions: Cost-effectiveness and cost-utility evidence was 
not equally perceived by decison makers and did not have equal weight in defining 
the official listing of biologic DMARDs for the treatment of RA. Further research 
should therefore address methods for a greater integration between health eco-
nomic analysis and final decisions taken by National HTA agencies.
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objeCtives: Although osteoporotic fractures impose a heavy financial burden on 
society as a whole, only 20% of patients with osteoporosis and in risk of fracture 
are being treated. The purpose of this study was to estimate the cost-effective-
ness of alendronate therapy for secondary prevention of osteoporotic fractures in 
Japan. Methods: A patient-level simulation model with nine health states was 
developed to predict lifetime costs and quality-adjusted life years (QALYs) of five 
years of alendronate therapy versus no preventive treatment for Japanese women 
with osteoporosis, who have a history of hip fracture. Fracture risk associated with 
age and bone mineral density (BMD) was derived from epidemiologic studies in 
Japan. We ran the model with different combinations of age (50, 60, and 70), BMD 
(T-score of −2.5 and −2.0), and BMD-independent fracture risk factors. Results: 
For patients with T-score of -2.0 having no additional risk factors, the incremental 
cost-effectiveness ratio (ICER) of alendronate was $3,023 and $7,389 per QALY gained 
for those aged 60 and 70 years, respectively. In all other situations, alendronate 
was dominant over no preventive treatment, with lifetime cost savings ranging 
from $30,849 to $1,498,961. These results were fairly robust to variations in model 
parameters. ConClusions: Alendronate therapy for secondary fracture prevention 
in Japanese women with osteoporosis provided good value for money.
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objeCtives: To assess clinical characteristics of RA patients considered suitable 
for biologic therapy (by their physicians) in comparison to those currently treated 
with 1st line biologics in the US. Methods: A medical chart-review study of RA 
patients was conducted among physicians (primarily rheumatologists) in hospitals/
